New insights to the crosstalk between vascular and bone tissue in chronic kidney disease–mineral and bone disorder

Publikation: Bidrag til tidsskriftReviewForskningfagfællebedømt

Standard

New insights to the crosstalk between vascular and bone tissue in chronic kidney disease–mineral and bone disorder. / Mace, Maria L.; Egstrand, Søren; Morevati, Marya; Olgaard, Klaus; Lewin, Ewa.

I: Metabolites, Bind 11, Nr. 12, 849, 2021.

Publikation: Bidrag til tidsskriftReviewForskningfagfællebedømt

Harvard

Mace, ML, Egstrand, S, Morevati, M, Olgaard, K & Lewin, E 2021, 'New insights to the crosstalk between vascular and bone tissue in chronic kidney disease–mineral and bone disorder', Metabolites, bind 11, nr. 12, 849. https://doi.org/10.3390/metabo11120849

APA

Mace, M. L., Egstrand, S., Morevati, M., Olgaard, K., & Lewin, E. (2021). New insights to the crosstalk between vascular and bone tissue in chronic kidney disease–mineral and bone disorder. Metabolites, 11(12), [849]. https://doi.org/10.3390/metabo11120849

Vancouver

Mace ML, Egstrand S, Morevati M, Olgaard K, Lewin E. New insights to the crosstalk between vascular and bone tissue in chronic kidney disease–mineral and bone disorder. Metabolites. 2021;11(12). 849. https://doi.org/10.3390/metabo11120849

Author

Mace, Maria L. ; Egstrand, Søren ; Morevati, Marya ; Olgaard, Klaus ; Lewin, Ewa. / New insights to the crosstalk between vascular and bone tissue in chronic kidney disease–mineral and bone disorder. I: Metabolites. 2021 ; Bind 11, Nr. 12.

Bibtex

@article{cec14df0c4144029807ed6a0acbaac1c,
title = "New insights to the crosstalk between vascular and bone tissue in chronic kidney disease–mineral and bone disorder",
abstract = "Vasculature plays a key role in bone development and the maintenance of bone tissue throughout life. The two organ systems are not only linked in normal physiology, but also in pathophysiological conditions. The chronic kidney disease–mineral and bone disorder (CKD-MBD) is still the most serious complication to CKD, resulting in increased morbidity and mortality. Current treatment therapies aimed at the phosphate retention and parathyroid hormone disturbances fail to reduce the high cardiovascular mortality in CKD patients, underlining the importance of other factors in the complex syndrome. This review will focus on vascular disease and its interplay with bone disorders in CKD. It will present the very late data showing a direct effect of vascular calcification on bone metabolism, indicating a vascular-bone tissue crosstalk in CKD. The calcified vasculature not only suffers from the systemic effects of CKD but seems to be an active player in the CKD-MBD syndrome impairing bone metabolism and might be a novel target for treatment and prevention.",
keywords = "Activin A, Dickkopf-1, Renal osteodystrophy, Sclerostin, TGF-β signaling, Tissue crosstalk, Uremic vasculopathy, Vascular calcification, Wnt pathway",
author = "Mace, {Maria L.} and S{\o}ren Egstrand and Marya Morevati and Klaus Olgaard and Ewa Lewin",
note = "Publisher Copyright: {\textcopyright} 2021 by the authors. Licensee MDPI, Basel, Switzerland.",
year = "2021",
doi = "10.3390/metabo11120849",
language = "English",
volume = "11",
journal = "Metabolites",
issn = "2218-1989",
publisher = "M D P I AG",
number = "12",

}

RIS

TY - JOUR

T1 - New insights to the crosstalk between vascular and bone tissue in chronic kidney disease–mineral and bone disorder

AU - Mace, Maria L.

AU - Egstrand, Søren

AU - Morevati, Marya

AU - Olgaard, Klaus

AU - Lewin, Ewa

N1 - Publisher Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland.

PY - 2021

Y1 - 2021

N2 - Vasculature plays a key role in bone development and the maintenance of bone tissue throughout life. The two organ systems are not only linked in normal physiology, but also in pathophysiological conditions. The chronic kidney disease–mineral and bone disorder (CKD-MBD) is still the most serious complication to CKD, resulting in increased morbidity and mortality. Current treatment therapies aimed at the phosphate retention and parathyroid hormone disturbances fail to reduce the high cardiovascular mortality in CKD patients, underlining the importance of other factors in the complex syndrome. This review will focus on vascular disease and its interplay with bone disorders in CKD. It will present the very late data showing a direct effect of vascular calcification on bone metabolism, indicating a vascular-bone tissue crosstalk in CKD. The calcified vasculature not only suffers from the systemic effects of CKD but seems to be an active player in the CKD-MBD syndrome impairing bone metabolism and might be a novel target for treatment and prevention.

AB - Vasculature plays a key role in bone development and the maintenance of bone tissue throughout life. The two organ systems are not only linked in normal physiology, but also in pathophysiological conditions. The chronic kidney disease–mineral and bone disorder (CKD-MBD) is still the most serious complication to CKD, resulting in increased morbidity and mortality. Current treatment therapies aimed at the phosphate retention and parathyroid hormone disturbances fail to reduce the high cardiovascular mortality in CKD patients, underlining the importance of other factors in the complex syndrome. This review will focus on vascular disease and its interplay with bone disorders in CKD. It will present the very late data showing a direct effect of vascular calcification on bone metabolism, indicating a vascular-bone tissue crosstalk in CKD. The calcified vasculature not only suffers from the systemic effects of CKD but seems to be an active player in the CKD-MBD syndrome impairing bone metabolism and might be a novel target for treatment and prevention.

KW - Activin A

KW - Dickkopf-1

KW - Renal osteodystrophy

KW - Sclerostin

KW - TGF-β signaling

KW - Tissue crosstalk

KW - Uremic vasculopathy

KW - Vascular calcification

KW - Wnt pathway

U2 - 10.3390/metabo11120849

DO - 10.3390/metabo11120849

M3 - Review

C2 - 34940607

AN - SCOPUS:85121756735

VL - 11

JO - Metabolites

JF - Metabolites

SN - 2218-1989

IS - 12

M1 - 849

ER -

ID: 303766497